100 related articles for article (PubMed ID: 28503915)
61. Reverse transcriptase fidelity and HIV-1 variation.
Keulen W; Nijhuis M; Schuurman R; Berkhout B; Boucher C
Science; 1997 Jan; 275(5297):229; author reply 230-1. PubMed ID: 8999550
[No Abstract] [Full Text] [Related]
62. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
[TBL] [Abstract][Full Text] [Related]
63. Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.
Neely M; Louie S; Xu J; Anthony P; Thuvamontolrat K; Mordwinkin N; Kovacs A
J Clin Pharmacol; 2015 Jul; 55(7):798-808. PubMed ID: 25683232
[TBL] [Abstract][Full Text] [Related]
64. [HIV infection and pregnancy. Improved therapy management for HIV infected pregnant patients].
MMW Fortschr Med; 2016 Jun; 158 Suppl 1():36-7. PubMed ID: 27259887
[No Abstract] [Full Text] [Related]
65. [Cutaneous CD8+ T-cell lymphoma. Regression after HIV antiviral triple therapy].
Santesteban Muruzábal R; Mitxelena Ezeiza J; Córdoba Iturriagagoitia A; Yanguas Bayona I
Med Clin (Barc); 2015 Dec; 145(11):e33-4. PubMed ID: 25865613
[No Abstract] [Full Text] [Related]
66. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
67. Atazanavir urolithiasis without recent intake of atazanavir.
Brunel V; Massy N; Malval B
Ann Biol Clin (Paris); 2019 Aug; 77(4):459-460. PubMed ID: 31418708
[No Abstract] [Full Text] [Related]
68. Response to letter to the editor: switch to dolutegravir and unboosted atazanavir.
Di Biagio A; Magnasco L; Cenderello G; Rizzardini G
AIDS; 2019 Nov; 33(14):2263-2264. PubMed ID: 31688044
[No Abstract] [Full Text] [Related]
69. Lenacapavir in first-line therapy.
Orkin C
Lancet HIV; 2023 Jan; 10(1):e2-e3. PubMed ID: 36566080
[No Abstract] [Full Text] [Related]
70. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.
Cahn P; Rolón MJ; Figueroa MI; Gun A; Patterson P; Sued O
J Int AIDS Soc; 2017 May; 20(1):21678. PubMed ID: 28537061
[TBL] [Abstract][Full Text] [Related]
71. Candidates for inclusion in a universal antiretroviral regimen: dolutegravir.
Cahn P
Curr Opin HIV AIDS; 2017 Jul; 12(4):318-323. PubMed ID: 28520610
[TBL] [Abstract][Full Text] [Related]
72. HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.
Charpentier C; Montes B; Perrier M; Meftah N; Reynes J
J Antimicrob Chemother; 2017 Oct; 72(10):2831-2836. PubMed ID: 29091218
[TBL] [Abstract][Full Text] [Related]
73. Dual antiretroviral therapy for HIV infection.
Soriano V; Fernandez-Montero JV; Benitez-Gutierrez L; Mendoza C; Arias A; Barreiro P; Peña JM; Labarga P
Expert Opin Drug Saf; 2017 Aug; 16(8):923-932. PubMed ID: 28621159
[TBL] [Abstract][Full Text] [Related]
74. Treatment Outcomes of Third-line Antiretroviral Regimens in HIV-infected Thai Adolescents.
Prasitsuebsai W; Sophonphan J; Chokephaibulkit K; Wongsawat J; Kanjanavanit S; Kosalaraksa P; Ngampiyakul C; Sangkla P; Hansudewechakul R; Kerr SJ; Puthanakit T; Ananworanich J;
Pediatr Infect Dis J; 2017 Oct; 36(10):967-972. PubMed ID: 28520611
[TBL] [Abstract][Full Text] [Related]
75. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
76. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
[TBL] [Abstract][Full Text] [Related]
77. The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen.
Venter WDF; Clayden P; Serenata C;
Curr Opin HIV AIDS; 2017 Jul; 12(4):351-354. PubMed ID: 28538284
[TBL] [Abstract][Full Text] [Related]
78. Treatment can be continued for mild cutaneous reactions associated with efavirenz.
Isaacs T; Ngwanya RM; Dlamini S; Peter J; Lehloenya R
J Allergy Clin Immunol Pract; 2019; 7(5):1676-1678. PubMed ID: 30529062
[No Abstract] [Full Text] [Related]
79. Photodermatitis in a woman on antiretroviral therapy: report of a rare cutaneous adverse drug reaction of efavirenz and review of literature.
Mahajan VK; Gupta S; Kohli S; Rashpa RS
Int J Dermatol; 2017 Oct; 56(10):e200-e202. PubMed ID: 28626988
[No Abstract] [Full Text] [Related]
80. Genomics of clonal evolution in a case of essential thrombocythemia.
Rashidi A; Nelson AC; Linden MA; Weisdorf DJ; Dolan MM; Ustun C
Leuk Lymphoma; 2018 Feb; 59(2):497-500. PubMed ID: 28604261
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
